This mechanism reverses cytarabine-induced Mcl-1/p-Chk1 resistance by targeting the NOXA/Mcl-1/Bim axis, offering a novel triple combination therapy for acute myeloid leukemia (Zhang et al., 2022). The gene discussed is BCL2L11; the disease is acute myeloid leukemia.